Rhythm Pharmaceuticals, Inc. (RYTM)

Rhythm Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	65.61	54.3	89.14	60.08	127.68	59.25
Short-Term Investments	265.28	334.65	231.43	215.77	205.61	235.61
Cash & Short-Term Investments	330.9	388.95	320.57	275.85	333.29	294.86
Cash Growth	13.70%	21.33%	16.21%	-17.23%	13.04%	70.64%
Receivables	40.41	26.08	18.51	14.87	6.22	1.03
Inventory	30.52	25.75	18.74	8.62	2.92	0.11
Other Current Assets	-	26.13	16.38	8.93	11.81	12.4
Total Current Assets	426.56	466.92	374.2	308.27	354.24	308.39
Property, Plant & Equipment	2.92	4.15	4.11	2.12	3.38	4.34
Other Intangible Assets	4.89	5.32	6.17	7.03	7.88	4.66
Long-Term Deferred Charges	-	1.66	6.21	12.59	-	-
Other Long-Term Assets	2.89	2.15	1.58	2.73	16.98	12.14
Total Assets	437.27	480.2	392.27	332.75	382.48	329.52

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	16.17	13.95	12.33	4.89	4.8	5.74
Accrued Expenses	86.7	79.78	58.31	42.85	30.48	29.26
Current Portion of Long-Term Debt	12.7	7.3	1.54	-	-	-
Current Portion of Leases	0.7	0.65	-	0.77	0.68	0.61
Current Unearned Revenue	-	0.19	1.29	1.29	1.43	7
Other Current Liabilities	7.31	4.08	42.05	5.41	2.42	0.83
Total Current Liabilities	123.59	105.94	115.52	55.2	39.81	43.43
Long-Term Debt	93.4	100.89	108.27	106.14	75.81	-
Long-Term Leases	2.98	3.34	3.94	0.49	1.26	1.95
Other Long-Term Liabilities	-	-	-	1.15	1.34	-
Total Liabilities	219.97	210.17	227.72	162.99	118.22	45.37

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.07	0.07	0.06	0.06	0.06	0.05
Additional Paid-In Capital	1,561	1,492	1,177	1,064	974.36	813.04
Retained Earnings	-1,457	-1,352	-1,155	-894.74	-710.06	-528.94
Comprehensive Income & Other	-0.91	-0.8	-0.04	0.13	-0.09	-0
Total Common Equity	102.98	139.07	21.73	169.76	264.26	284.15
Shareholders' Equity	217.3	270.03	164.55	169.76	264.26	284.15
Total Liabilities & Equity	437.27	480.2	392.27	332.75	382.48	329.52

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	109.78	112.17	113.75	107.4	77.75	2.55
Net Cash (Debt)	221.11	276.78	206.82	168.44	255.53	292.3
Net Cash Growth	24.89%	33.83%	22.78%	-34.08%	-12.58%	72.24%
Net Cash Per Share	3.28	4.26	3.39	2.92	4.90	5.89
Filing Date Shares Outstanding	68.85	68.29	63.22	60.14	56.75	50.33
Total Common Shares Outstanding	68.82	67.21	62.39	59.43	56.61	50.28
Working Capital	302.98	360.97	258.68	253.07	314.43	264.96
Book Value Per Share	1.50	2.07	0.35	2.86	4.67	5.65
Tangible Book Value	98.09	133.75	15.56	162.73	256.38	279.49
Tangible Book Value Per Share	1.43	1.99	0.25	2.74	4.53	5.56
Machinery	-	2.69	2.69	2.7	2.65	2.37
Construction In Progress	-	0.93	-	-	-	-
Leasehold Improvements	-	2.73	2.71	2.71	2.71	2.71

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error